Madan R, Gulley J, Dahut W, et al . Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA -TRICOM, in the treatment of metastatic, castrate- resistant prostate cancer (mCRPC): implications for clinical trial design [abstract]. J Clin Oncol 2008;26(20S):3005. Protocol BNIT -PRV- 301; Amendment 7 PROSTVAC -V/F Version 2.7, 08 February 2017 CONFIDENTIAL AND RESTRICTED 77 Amend 7 Disclosure requires written consent from Bavarian Nordic , Inc. 51.